References
- 1. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo, JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51.
- 2. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010;163:269-74.
- 3. Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol 2010;146:564-5.
- 4. Ni N, Langer P, Wagner R, Guo S. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol 2011;129:377-9.
- 5. Blatt J, Morrell DS, Buck S, Zdanski C, Gold S, Stavas J, et al. {beta}-Blockers for Infantile Hemangiomas: A Single-Institution Experience. Clin Pediatr (Phila) 2011;50:757-63.
- 6. Chakkittakandiyil A, Phillips R, Frieden IJ, Siegfried E, Lara- Corrales I, Lam J, et al. Timolol Maleate 0.5% or 0.1% Gel- Forming Solution for Infantile Hemangiomas: A Retrospective, Multicenter, Cohort Study. Pediatr Dermatol. 2011; [Epub ahead of print].
- 7. Volotinen M, Hakkola J, Pelkonen O, Vapaatalo H, Maenpaa J. Metabolism of ophthalmic timolol: new aspects of an olddrug. Basic Clin Pharmacol Toxicol 2011;108:297-303.
- 8. Zimmerman TJ, Kooner KS, Morgan KS. Safety and efficacy of timolol in pediatric glaucoma. Surv Ophthalmol 1983;28:262-4.
- 9. Kubota K, Yamada T, Kikuchi K, Koyama E, Ishizaki T. Pharmacokinetics and beta-blocking effects of transdermal timolol. Eur J Clin Pharmacol 1993;44:493-5.
- 10. Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010;128:255-6.
- 11. O’Loughlin A, O’Donnell B, Watson R. Mature infantile haemangiomas role for propranolol. J Eur Acad Dermatol Venereol 2010;25:1363-4.
- 12. Khunger N, Pahwa M. Dramatic response to topical timolol lotion of a large hemifacial infantile haemangioma associated with PHACE syndrome. Br J Dermatol 2011;164:886-8.
- 13. K, Kunzi-Rapp. Topical Propranolol Therapy for Infantile Hemangiomas. Pediatr Dermatol 2011; [Epub ahead of print].
- 14. Ademola JI, Chow CA, Wester RC, Maibach HI. Metabolism of propranolol during percutaneous absorption in human skin. J Pharm Sci 1993;82:767-70.
- 15. Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. Interactions between novel terpenes and main components of rat and human skin: mechanistic view for transdermal delivery of propranolol hydrochloride. Curr Drug Deliv 2011;8:213-24.
- 16. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol 2003;139:1347-50.
- 17. Sidbury R, Neuschler N, Neuschler E, Sun P, Wang XQ, Miller R, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003;121:1205-9.
- 18. Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, Wessels MR. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 2004;173:4627-4.
- 19. Martinez MI, Sanchez-Carpintero I, North Pe, Mihm MC. Infantile haemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002;138:881-4.
- 20. Ho NTC, Lansang P, Pope E. Topical imiquimod in the treatment of infantile haemangiomas: A retrospective study. J Am Acad Dermatol 2007;56:63-8.
- 21. McCuaig CC, Dubois J, Powell J, Belleville C, David M, Rousseau E, et al. A Phase II, Open-Label Study of the Efficacyand Safety of Imiquimod in the Treatment of Superficial and Mixed Infantile Hemangioma. Pediatr Dermatol 2009;26:203-12.
- 22. Welsh O, Olazaran Z, Gomez M, Salas J, Berman B. Treatment of infantile haemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 2004;51:639-42.
- 23. Barry RBM, Hughes BR, Cook LJ. Involution of infantile haemangiomas after imiquimod 5% cream. Clin Exp Dermatol 2008;33:446-9.
- 24. Jiang C, Hu X, Ma G, Chen D, Jin Y, Chen H, et al. A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma. Pediatr Dermatol. 2011;28:259-66.
- 25. Myhre PE, Levy ML, Eichenfield LF, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children. Pediatr Dermatol 2008;25:88-95.
- 26. Hussain W, Judge MR. The role of imiquimod in treating infantile haemangiomas: cause for concern? Clin Exp Dermatol 2009;34:e257.
- 27. Elsas FJ, Lewis AR. Topical treatment of periocular capillary hemangioma. J Pediatr Ophthalmol Strabismus. 1994;31:153-6.
- 28. Cruz OA, Zarnegar SR, Myers SE. Treatment of periocular capillary hemangioma with topical clobetasol propionate. Ophthalmology 1995;102:2012-5.
- 29. Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol 2005;52:281-6.
- 30. Pandey A, Gangopadhyay AN, Sharma SP, Kumar V, Gupta DK, Gopal SC. Evaluation of topical steroids in the treatment of superficial hemangioma. Skinmed 2010;8:9-11.
- 31. Greenberger S, Adini I, Boscolo E, Mulliken JB, Bischoff J. Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 2010;13:327-35.
- 32. Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Corticosteroid suppression of VEGF-A in infantile hemangiomaderived stem cells. N Engl J Med 2010;362:1005-13.
- 33. Sugarman JL, Mauro TM, Frieden IJ. Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor. Arch Dermatol 2002;138:314-6.
- 34. Metz BJ, Rubenstein MC, Levy ML, Metry DW. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 2004;140:867-70.
- 35. Frieden IJ. Addendum: Commentary on becaplermin gel (Regranex) for hemangiomas. Pediatr Dermatol 2008;25:590.